Zobrazeno 1 - 10
of 32
pro vyhledávání: '"V. G. Moroz"'
Autor:
M. V. Maevskaya, M. Yu. Nadinskaia, E. N. Bessonova, N. I. Geyvandova, M. S. Zharkova, E. A. Kitsenko, N. V. Korochanskaya, I. A. Kurkina, A. L. Melikyan, V. G. Morozov, Yu. V. Khoronko, T. A. Deeva, K. A. Gulyaeva, V. T. Ivashkin
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 34, Iss 3, Pp 115-134 (2024)
Introduction. As a result of portal hypertension (sequestration of platelets in an enlarged spleen) and liver failure (decreased production of thrombopoietin in the liver) in liver cirrhosis, thrombocytopenia develops, which is associated with the ri
Externí odkaz:
https://doaj.org/article/b386bf93f6834d9dbfe6e6aca09034ee
Autor:
О. I. Sagalova, V. S. Adonieva, S. V. Zotov, D. A. Gusev, E. A. Strebkova, R. B. Galbraikh, V. G. Morozov, I. M. Khayertynova, I. V. Krasilnikova, I. V. Sannikova, A. Bhagat, D. O. Milenin, A. P. Efremova
Publikováno v:
Журнал инфектологии, Vol 15, Iss 2, Pp 47-59 (2023)
Background: Glecaprevir/pibrentasvir (GLE/PIB) is the first pangenotypic ribavirin-free regimen allowing for treatment duration as short as 8 weeks for the majority of patients with chronic hepatitis C (CHC) genotypes (GT) 1 to 6. The results of clin
Externí odkaz:
https://doaj.org/article/389b88fc374c48f6a2ff599607676be3
Autor:
T. K. Dzagurova, R. T. Murzabaeva, F. G. Kutluguzhina, V. G. Morozov, E. V. Volnyh, S. S. Kurashova, M. V. Balovneva, P. E. Tkachenko, A. A. Ishmukhametov, A. V. Belyakova, E. A. Tkachenko
Publikováno v:
Инфекция и иммунитет, Vol 12, Iss 3, Pp 527-534 (2022)
Relevance. Hemorrhagic fever with renal syndrome (HFRS) is an acute viral zoonosis. Being widespread in Eurasia, it holds a leading place in Russia among natural focal human diseases. The vast majority of HFRS cases in Russia, about 98%, are associat
Externí odkaz:
https://doaj.org/article/3fb94f27c0fc48298d11a85550ec3bb2
Autor:
A. F. Berman, V. G. Moroz
Publikováno v:
Strength of Materials. 25:108-112
Investigations were carried out into the mechanisms, kinetics, and dynamics of the physicomechanical factors determining damage and brittle fracture of pipes of low-alloy steel of the ferritic-pearlitic grade. The results show that due to hydrogen ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b564e3831a1f6b442211943c315a060
https://doi.org/10.1007/bf00782189
https://doi.org/10.1007/bf00782189
Autor:
T. K. Dzagurova, A. A. Ishmukhametov, V. A. Bakhtina, V. G. Morozov, M. V. Balovneva, S. S. Kurashova, B. .. Klempa, D. .. Kruger, E. A. Tkachenko
Publikováno v:
Вопросы вирусологии, Vol 64, Iss 1, Pp 36-41 (2019)
Introduction. Hemorrhagic fever with renal syndrome (HFRS) occupies a leading place among natural focal human diseases in the Russian Federation. Sporadic incidence of HFRS-Sochi has been annually recorded in the Krasnodar Territory since 2000. The g
Externí odkaz:
https://doaj.org/article/3d8f97163ebf49e1b69b71f1403717d4
Autor:
V. V. Ignatyuk, V. G. Morozov
Publikováno v:
Condensed Matter Physics, Vol 25, Iss 1, p 13302 (2022)
The non-Markovian master equation for open quantum systems is obtained by generalization of the standard Zwanzig-Nakajima (ZN) projection technique. To this end, a coupled chain of equations is written for the reduced density matrices of the bath ϱ(
Externí odkaz:
https://doaj.org/article/c3811c72beaf46a49843571fd57dc821
Autor:
I. G. Bakulin, N. A. Bokhan, P. O. Bogomolov, N. I. Geyvandova, M. V. Matsiyevich, M. A. Vinnikova, V. G. Morozov, O. M. Khromtsova, G. S. Soldatova, O. Yu. Shiryayev, R. D. Ilyuk, K. V. Rybakova, A. G. Katkovskaya, S. V. Teplykh, A. A. Bagretsova, M. V. Krasnova, Ye. V. Alekseyeva, A. V. Anipchenko, Ye. V. Baskakov
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 27, Iss 3, Pp 57-68 (2018)
Material and methods. The original study included overall 120 patients with ALD, who were randomized in two identical groups. The patients of the main group (group A) received 2 courses of therapy: the first - Phosphogliv 5 mg/day as intravenous bolu
Externí odkaz:
https://doaj.org/article/4f495eb6776240bda9501c18da8c6da0
Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial)
Autor:
Marina V. Mayevskaya, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda, V. T. Ivashkin
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 26, Iss 6, Pp 69-83 (2018)
Aim of investigation. Nowadays the question, whether pegylated interferon should be completely abandoned in the treatment of chronic hepatitis C (CHC) is still open. Beneficial interferon properties include: absence of mutagenic capacity for hepatiti
Externí odkaz:
https://doaj.org/article/14e4f35f52b640b1807d773161107b05
Autor:
V. T. Ivashkin, M. V. Mayevskaya, D. T. Abdurakhmanov, I. G. Bakulin, N. I. Geyvandova, M. L. Zubkin, S. N. Kizhlo, A. V. Kuznetsova, I. B. Latysheva, N. A. Mamonova, V. G. Morozov, O. I. Sagalova, Ye. V. Esaulenko, Ye. O. Lyusina
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 27, Iss 6, Pp 52-62 (2018)
Introduction. The options of antiviral therapy (AVT) in the stages of severe liver fibrosis and cirrhosis (LC) as well as in the patients with comorbidities for the long time were limited to the standard therapy by pegilated interferon (peg-IFN) in c
Externí odkaz:
https://doaj.org/article/648fb9a0265848459515bd7b7ee40f58
Autor:
M. V. Mayevskaya, V. T. Ivashkin, O. O. Znoyko, Ye. A. Klimova, D. T. Abdurakhmanov, I. G. Bakulin, P. O. Bogomolov, E. Z. Burnevich, M. Yu. Galushko, N. I. Geyvandova, K. V. Zhdanov, Ye. V. Esaulenko, S. N. Kizhlo, D. Yu. Konstantinov, N. I. Mironova, V. G. Morozov, Ye. A. Strebkova, I. G. Nikitin, M. F. Osipenko, V. D. Pasechnikov, O. I. Sagalova, I. M. Khayertynova, V. P. Chulanov, A. A. Yakovlev, I. A. Vasyutin, Ye. P. Tarkhova, E. N. Krasavina, M. Yu. Samsonov
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 27, Iss 6, Pp 41-51 (2018)
Aim of investigation. To estimate efficacy and safety of narlaprevir (NVR) with ritonavir (RTV), pegilated interferon (peg-IFN) and ribavirin (RBV) at treatmentnaïve and earlier treated noncirrhotic patients with chronic hepatitis C caused by the 1s
Externí odkaz:
https://doaj.org/article/0686acb179664d0d893a6a2414c4957c